BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 16443723)

  • 1. In vivo characterization of Abeta(40) changes in brain and cerebrospinal fluid using the novel gamma-secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) in the rat.
    Best JD; Jay MT; Otu F; Churcher I; Reilly M; Morentin-Gutierrez P; Pattison C; Harrison T; Shearman MS; Atack JR
    J Pharmacol Exp Ther; 2006 May; 317(2):786-90. PubMed ID: 16443723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The novel gamma secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) reduces amyloid plaque deposition without evidence of notch-related pathology in the Tg2576 mouse.
    Best JD; Smith DW; Reilly MA; O'Donnell R; Lewis HD; Ellis S; Wilkie N; Rosahl TW; Laroque PA; Boussiquet-Leroux C; Churcher I; Atack JR; Harrison T; Shearman MS
    J Pharmacol Exp Ther; 2007 Feb; 320(2):552-8. PubMed ID: 17099072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative measurement of changes in amyloid-beta(40) in the rat brain and cerebrospinal fluid following treatment with the gamma-secretase inhibitor LY-411575 [N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide].
    Best JD; Jay MT; Otu F; Ma J; Nadin A; Ellis S; Lewis HD; Pattison C; Reilly M; Harrison T; Shearman MS; Williamson TL; Atack JR
    J Pharmacol Exp Ther; 2005 May; 313(2):902-8. PubMed ID: 15743924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reductions in beta-amyloid concentrations in vivo by the gamma-secretase inhibitors BMS-289948 and BMS-299897.
    Anderson JJ; Holtz G; Baskin PP; Turner M; Rowe B; Wang B; Kounnas MZ; Lamb BT; Barten D; Felsenstein K; McDonald I; Srinivasan K; Munoz B; Wagner SL
    Biochem Pharmacol; 2005 Feb; 69(4):689-98. PubMed ID: 15670587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative assessment of Aβ peptide in brain, cerebrospinal fluid and plasma following oral administration of γ-secretase inhibitor MRK-560 in rats.
    Wu G; Wu Z; Na S; Hershey JC
    Int J Neurosci; 2015; 125(8):616-24. PubMed ID: 25567290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor.
    Barten DM; Guss VL; Corsa JA; Loo A; Hansel SB; Zheng M; Munoz B; Srinivasan K; Wang B; Robertson BJ; Polson CT; Wang J; Roberts SB; Hendrick JP; Anderson JJ; Loy JK; Denton R; Verdoorn TA; Smith DW; Felsenstein KM
    J Pharmacol Exp Ther; 2005 Feb; 312(2):635-43. PubMed ID: 15452193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased axonal transport rates in the Tg2576 APP transgenic mouse: improvement with the gamma-secretase inhibitor MRK-560 as detected by manganese-enhanced MRI.
    Wang FH; Appelkvist P; Klason T; Gissberg O; Bogstedt A; Eliason K; Martinsson S; Briem S; Andersson A; Visser SA; Ivarsson M; Lindberg M; Agerman K; Sandin J
    Eur J Neurosci; 2012 Nov; 36(9):3165-72. PubMed ID: 22958226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease.
    Martone RL; Zhou H; Atchison K; Comery T; Xu JZ; Huang X; Gong X; Jin M; Kreft A; Harrison B; Mayer SC; Aschmies S; Gonzales C; Zaleska MM; Riddell DR; Wagner E; Lu P; Sun SC; Sonnenberg-Reines J; Oganesian A; Adkins K; Leach MW; Clarke DW; Huryn D; Abou-Gharbia M; Magolda R; Bard J; Frick G; Raje S; Forlow SB; Balliet C; Burczynski ME; Reinhart PH; Wan HI; Pangalos MN; Jacobsen JS
    J Pharmacol Exp Ther; 2009 Nov; 331(2):598-608. PubMed ID: 19671883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction of Abeta levels in the Sprague Dawley rat after oral administration of the functional gamma-secretase inhibitor, DAPT: a novel non-transgenic model for Abeta production inhibitors.
    El Mouedden M; Vandermeeren M; Meert T; Mercken M
    Curr Pharm Des; 2006; 12(6):671-6. PubMed ID: 16472156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute effect on the Aβ isoform pattern in CSF in response to γ-secretase modulator and inhibitor treatment in dogs.
    Portelius E; Van Broeck B; Andreasson U; Gustavsson MK; Mercken M; Zetterberg H; Borghys H; Blennow K
    J Alzheimers Dis; 2010; 21(3):1005-12. PubMed ID: 20634579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cisterna magna cannulated repeated CSF sampling rat model--effects of a gamma-secretase inhibitor on Aβ levels.
    Shapiro JS; Stiteler M; Wu G; Price EA; Simon AJ; Sankaranarayanan S
    J Neurosci Methods; 2012 Mar; 205(1):36-44. PubMed ID: 22226743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamics of Aβ42 reduction in plasma, CSF and brain of rats treated with the γ-secretase modulator, GSM-10h.
    Hawkins J; Harrison DC; Ahmed S; Davis RP; Chapman T; Marshall I; Smith B; Mead TL; Medhurst A; Giblin GM; Hall A; Gonzalez MI; Richardson J; Hussain I
    Neurodegener Dis; 2011; 8(6):455-64. PubMed ID: 21389687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies of Abeta pharmacodynamics in the brain, cerebrospinal fluid, and plasma in young (plaque-free) Tg2576 mice using the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY-411575).
    Lanz TA; Hosley JD; Adams WJ; Merchant KM
    J Pharmacol Exp Ther; 2004 Apr; 309(1):49-55. PubMed ID: 14718585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Orally bioavailable and brain-penetrant pyridazine and pyridine-derived γ-secretase modulators reduced amyloidogenic Aβ peptides in vivo.
    Huang Y; Li T; Eatherton A; Mitchell WL; Rong N; Ye L; Yang XJ; Jin S; Ding Y; Zhang J; Li Y; Wu Y; Jin Y; Sang Y; Cheng Z; Browne ER; Harrison DC; Hussain I; Wan Z; Hall A; Lau LF; Matsuoka Y
    Neuropharmacology; 2013 Jul; 70():278-86. PubMed ID: 23485401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining an amyloid-beta (Aβ) cleaving enzyme inhibitor with a γ-secretase modulator results in an additive reduction of Aβ production.
    Strömberg K; Eketjäll S; Georgievska B; Tunblad K; Eliason K; Olsson F; Radesäter AC; Klintenberg R; Arvidsson PI; von Berg S; Fälting J; Cowburn RF; Dabrowski M
    FEBS J; 2015 Jan; 282(1):65-73. PubMed ID: 25303711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 4-substituted cyclohexyl sulfones as potent, orally active gamma-secretase inhibitors.
    Churcher I; Beher D; Best JD; Castro JL; Clarke EE; Gentry A; Harrison T; Hitzel L; Kay E; Kerrad S; Lewis HD; Morentin-Gutierrez P; Mortishire-Smith R; Oakley PJ; Reilly M; Shaw DE; Shearman MS; Teall MR; Williams S; Wrigley JD
    Bioorg Med Chem Lett; 2006 Jan; 16(2):280-4. PubMed ID: 16275079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamics of selective inhibition of γ-secretase by avagacestat.
    Albright CF; Dockens RC; Meredith JE; Olson RE; Slemmon R; Lentz KA; Wang JS; Denton RR; Pilcher G; Rhyne PW; Raybon JJ; Barten DM; Burton C; Toyn JH; Sankaranarayanan S; Polson C; Guss V; White R; Simutis F; Sanderson T; Gillman KW; Starrett JE; Bronson J; Sverdlov O; Huang SP; Castaneda L; Feldman H; Coric V; Zaczek R; Macor JE; Houston J; Berman RM; Tong G
    J Pharmacol Exp Ther; 2013 Mar; 344(3):686-95. PubMed ID: 23275065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Method for the determination of the levels of beta-amyloid peptide in the CSF sampled from freely moving rats.
    El Mouedden M; Haseldonckx M; Mackie C; Meert T; Mercken M
    J Pharmacol Toxicol Methods; 2005; 52(2):229-33. PubMed ID: 16125620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BIIB042, a novel γ-secretase modulator, reduces amyloidogenic Aβ isoforms in primates and rodents and plaque pathology in a mouse model of Alzheimer's disease.
    Scannevin RH; Chollate S; Brennan MS; Snodgrass-Belt PA; Peng H; Xu L; Jung MY; Bussiere T; Arastu MF; Talreja T; Xin Z; Dunstan RW; Fahrer D; Rohde E; Dunah AW; Wang J; Kumaravel G; Taveras AG; Moore Arnold H; Rhodes KJ
    Neuropharmacology; 2016 Apr; 103():57-68. PubMed ID: 26690893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of gamma-secretase and BACE1 inhibition on brain Abeta levels in vitro and in vivo.
    Elvang AB; Volbracht C; Pedersen LØ; Jensen KG; Karlsson JJ; Larsen SA; Mørk A; Stensbøl TB; Bastlund JF
    J Neurochem; 2009 Sep; 110(5):1377-87. PubMed ID: 19519664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.